Ozempic solution for injection

Ozempic is a prescription medication containing semaglutide, developed by the Danish pharmaceutical giant Novo Nordisk. Originally approved for the treatment of type 2 diabetes, it has gained global recognition for its weight management benefits.

The brand is fundamentally Danish, with its headquarters and primary manufacturing facilities located in Bagsværd, Denmark. However, due to immense global demand, production has expanded to several international sites, including the United States, France, and Brazil.

Novo Nordisk remains the ultimate owner and operator of the brand. As a world leader in diabetes care, the company is majority-owned by the Novo Nordisk Foundation, ensuring a focus on long-term medical research and stability.